The safety profile of nefazodone

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 2, 1996, Pages 31-38

  Robinson, Donald S ^a   Roberts, Douglas L ^b   Smith, Jeanne M ^b   Stringfellow, Joseph C ^b   Kaplita, Stephen B ^b   Seminara, Jesse A ^b   Marcus, Ronald N ^b,c  

^a Bristol Myers Squibb P ^*

^b BRISTOL MYERS SQUIBB   (United States)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPRAZOLAM; AMITRIPTYLINE; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ASTEMIZOLE; CIMETIDINE; CLOMIPRAMINE; DIGOXIN; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LORAZEPAM; METHOCARBAMOL; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PHENYTOIN; PLACEBO; PROPRANOLOL; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TERFENADINE; THEOPHYLLINE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG OVERDOSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SUICIDE ATTEMPT; TREATMENT OUTCOME; VISUAL IMPAIRMENT; XEROSTOMIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FLUOXETINE; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PLACEBOS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME; TRIAZOLES; WEIGHT GAIN;

EID: 0029917943     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone: a novel antidepressant drug. J Clin Psychiatry 1995;56 (suppl 6):3-11
2. Beasley CM, Dorseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303:685-692
3. Beasley CM Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991; 52:294-299
4. Beasley CM, Sayler ME, Bosomworth JC, et al. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol 1991;11:166-174
5. Lipinski JF Jr, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989;50: 339-342
6. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991;52: 491-493
7. Altshuler LL. Fluoxetine-associated panic attacks. J Clin Psychopharmacol 1994;14:433-434
8. Fawcett J. Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995;56(suppl 6):37-42
9. Zajecka J, Fawcett J, Schaff M, et al. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991;52:66-68
10. Seagraves RT. Overview of sexual dysfunction complicating the treatment of depression. J Clin Psychiatry Monograph 1992;10(2):4-10
11. Settle EC Jr. Antidepressant side effects: issues and options. J Clin Psychiatry Monograph 1992;10(1):48-61
12. Caplik J, Talukder E, Roberts D, et al. Nefazodone and body weight change: a comparison of nefazodone and imipramine in placebo-controlled trials of treatment for major depression. Neuropsychopharmacology 1994;10(suppl 3, pt 2). Abstract P-17-32:220S
13. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713
14. Breuel H-P, DeLeenheer I, Coninx L, et al Comparisons of the cardiovascular effects of nefazodone, imipramine, and placebo in healthy elderly volunteers [abstract]. Eur Neuropsychopharmacol 1993;Sept [special issue] :423
15. Cohn CK. 5-HT antidepressants in the elderly: a 10-year experience In. Bergener M, Belmaker RH, Tropper MS, eds. Psychopharmacotherapy for the Elderly: Research and Clinical Implications. New York, NY: Springer, 1993:328-343
16. Sainati S, Shukla U, Chaikin P, et al. The single and multiple dose pharmacokinetics of nefazodone in healthy volunteers and subjects with hepatic impairment [abstract]. J Clin Pharmacol 1992;32:756
17. Shea JP, Shukla UA, Pittman KA. Single dose pharmacokinetics of nefazodone in elderly subjects, renally impaired patients, and patients with hepatic cirrhosis in comparison to healthy volunteers. Clin Pharmacol Ther 1988;43. Abstract PIIA-5:146
18. Marathe P, Uderman H, Raymond R, et al. Pharmacokinetics and pharmacodynamics of nefazodone and propranolol co-administration [abstract]. Neuropsychopharmacology 1994;11(4):276
19. Greene DS, Dockens RC, Salazar DE, et al. Coadmirustration of nefazodone and benzodiazepines, I: pharmacokinetic assessment [abstract]. Clin Pharmacol Ther 1994;55:141
20. Fewer LJ, Lader M. The effects of nefazodone, imipramine, and placebo, alone and combined with alcohol in normal subjects, Int Clin Psychopharmacol 1993;8:13-20